Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years: randomised clinical trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years : randomised clinical trial. / Vinding, Rebecca Kofod; Stokholm, Jakob; Sevelsted, Astrid; Sejersen, Tobias; Chawes, Bo L; Bønnelykke, Klaus; Thorsen, Jonathan; Howe, Laura D; Krakauer, Martin; Bisgaard, Hans.
I: BMJ (Clinical research ed.), Bind 362, k3312, 2018, s. 1-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years
T2 - randomised clinical trial
AU - Vinding, Rebecca Kofod
AU - Stokholm, Jakob
AU - Sevelsted, Astrid
AU - Sejersen, Tobias
AU - Chawes, Bo L
AU - Bønnelykke, Klaus
AU - Thorsen, Jonathan
AU - Howe, Laura D
AU - Krakauer, Martin
AU - Bisgaard, Hans
N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PY - 2018
Y1 - 2018
N2 - OBJECTIVE: To examine the effect of supplementation with n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) in pregnancy on anthropometry and body composition in offspring.DESIGN: Double blinded, randomised controlled trial.SETTING: Copenhagen Prospective Studies on Asthma in Childhood2010 cohort.PARTICIPANTS: 736 pregnant women and their offspring.INTERVENTION: n-3 LCPUFA (fish oil) or control (olive oil) daily from pregnancy week 24 until one week after birth.MAIN OUTCOME MEASURES: Height/length, weight, head, and waist measurements and body composition from dual energy x ray absorptiometry (all pre-specified secondary endpoints of the n-3 LCPUFA trial; the primary outcome for the trial was persistent wheeze/asthma).RESULTS: The mean body mass index (BMI) z score was increased between age 0 and 6 years in the fish oil supplementation group compared with the control group (0.14 (95% confidence interval 0.04 to 0.23); P=0.006). At 6 years, supplementation was associated with a higher BMI z score (0.19 (0.06 to 0.32); P=0.004), a higher weight/height (3.48 (0.38 to 6.57) g/cm; P=0.03), and a larger waist circumference (0.6 (0.0 to 1.2) cm; P=0.04) but not a higher proportion of obese children, using International Obesity Task Force grades. The dual energy x ray absorptiometry scan at age 6 years showed a higher total mass (395.4 (86.6 to 704.3) g; P=0.01) in the supplementation versus the control group, explained by a higher lean mass (280.7 (98.9 to 462.4) g; P=0.002), a higher bone mineral content (10.3 (2.3 to 18.1) g; P=0.01), and a non-significantly higher fat mass (116.3 (-92.9 to 325.5) g; P=0.28), but no differences were seen in total body fat or lean mass percentage.CONCLUSION: Fish oil supplementation from the 24th week of pregnancy led to a higher BMI in the offspring from 0 to 6 years of age but not an increased risk of obesity at age 6. The body composition at age 6 years in children given fish oil supplementation was characterised by a proportional increase in lean, bone, and fat mass suggesting a general growth stimulating effect of n-3 LCPUFA.TRIAL REGISTRATION: Clinicaltrials.gov NCT00798226.
AB - OBJECTIVE: To examine the effect of supplementation with n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) in pregnancy on anthropometry and body composition in offspring.DESIGN: Double blinded, randomised controlled trial.SETTING: Copenhagen Prospective Studies on Asthma in Childhood2010 cohort.PARTICIPANTS: 736 pregnant women and their offspring.INTERVENTION: n-3 LCPUFA (fish oil) or control (olive oil) daily from pregnancy week 24 until one week after birth.MAIN OUTCOME MEASURES: Height/length, weight, head, and waist measurements and body composition from dual energy x ray absorptiometry (all pre-specified secondary endpoints of the n-3 LCPUFA trial; the primary outcome for the trial was persistent wheeze/asthma).RESULTS: The mean body mass index (BMI) z score was increased between age 0 and 6 years in the fish oil supplementation group compared with the control group (0.14 (95% confidence interval 0.04 to 0.23); P=0.006). At 6 years, supplementation was associated with a higher BMI z score (0.19 (0.06 to 0.32); P=0.004), a higher weight/height (3.48 (0.38 to 6.57) g/cm; P=0.03), and a larger waist circumference (0.6 (0.0 to 1.2) cm; P=0.04) but not a higher proportion of obese children, using International Obesity Task Force grades. The dual energy x ray absorptiometry scan at age 6 years showed a higher total mass (395.4 (86.6 to 704.3) g; P=0.01) in the supplementation versus the control group, explained by a higher lean mass (280.7 (98.9 to 462.4) g; P=0.002), a higher bone mineral content (10.3 (2.3 to 18.1) g; P=0.01), and a non-significantly higher fat mass (116.3 (-92.9 to 325.5) g; P=0.28), but no differences were seen in total body fat or lean mass percentage.CONCLUSION: Fish oil supplementation from the 24th week of pregnancy led to a higher BMI in the offspring from 0 to 6 years of age but not an increased risk of obesity at age 6. The body composition at age 6 years in children given fish oil supplementation was characterised by a proportional increase in lean, bone, and fat mass suggesting a general growth stimulating effect of n-3 LCPUFA.TRIAL REGISTRATION: Clinicaltrials.gov NCT00798226.
KW - Absorptiometry, Photon
KW - Adult
KW - Body Mass Index
KW - Bone Density/drug effects
KW - Bone Development/drug effects
KW - Child
KW - Dietary Supplements
KW - Double-Blind Method
KW - Fatty Acids, Omega-3/administration & dosage
KW - Female
KW - Fish Oils/administration & dosage
KW - Humans
KW - Infant
KW - Infant Nutritional Physiological Phenomena
KW - Maternal Nutritional Physiological Phenomena
KW - Pregnancy
KW - Prenatal Care
KW - Prenatal Exposure Delayed Effects
KW - Prospective Studies
U2 - 10.1136/bmj.k3312
DO - 10.1136/bmj.k3312
M3 - Journal article
C2 - 30181143
VL - 362
SP - 1
EP - 9
JO - The BMJ
JF - The BMJ
SN - 0959-8146
M1 - k3312
ER -
ID: 220857492